EUCTR2004-005172-17-DE进行中（未招募）1 期
Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media - RenalFlowH
Charité/Campus Virchow-Klinikum, Medizinische Klinik m. S. Kardiologie0 个研究点目标入组 30 人开始时间: 2006年5月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- clinical need for left ventricular (LV) and coronary angiography with or without percutaneous intervention (depending on the result of the diagnostic study)
- •- chronic renal failure with GFR < 50ml/min
- •- informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- age < 18 years
- •- stenosis of renal artery
- •- life expectancy below 6 months
- •- insufficient German language skills
- •- chronic renal replacement therapy
研究者
相似试验
招募中
2 期
Comparative study of hemodynamic and renal effects of Pethidine and Marcaine during and after surgery in patients undergoing ureteral stone surgeryrological services with urine virtual stone.Calculus of lower urinary tractIRCT20130812014333N165Kermanshah University of Medical Sciences66
已完成
不适用
Effects of contrast media for residual renal function in peritoneal dialysis patients.End-Stage Renal Disease (ESRD)JPRN-UMIN000013948agoya University100
尚未招募
不适用
Renal function after pulsatile blood flow during cardiopulmonary bypass in cardiac surgeryCardiac surgeryRenal functionCardiopulmonary bypassNL-OMON21086VU University Medical CenterUMCG294
招募中
不适用
REnal function after PULSatile blood flow during cardiopulmonary bypass in cardiac surgeryacute kidney injuryNL-OMON47075Vrije Universiteit Medisch Centrum294
已完成
2 期
Analysis of renal function during angiostatic therapy with the COX-II inhibitor rofecoxib, in combination with pioglitazone, and trofosfamide or capecitabine in patients with metastatic / advanced cancer.C80Malignant neoplasm, without specification of siteDRKS00000119Abteilung für Hämatologie und Internistische OnkologieKlinikum der Universität Regensburg87